|
Lundbeck enters into drug discovery collaboration with Zenobia and Vernalis
|
16 December 2010 |
|
Lundbeck to establish a strong, dedicated sales force behind Lexapro® in China
|
14 December 2010 |
|
Lundbeck expects to deliver solid profits during a period of new product launches and patent expiries
|
03 November 2010 |
|
Lundbeck and Genmab enter into a research collaboration
|
14 October 2010 |
|
Lundbeck and Merck sign exclusive commercialisation agreement for SYCREST®
|
12 October 2010 |
|
Lundbeck enters into license agreement with Kyowa Hakko Kirin for A2a antagonists
|
06 October 2010 |
|
Lundbeck reports strongly increasing profits with EBIT growth of 30%
|
13 August 2010 |
|
TEMPO study further demonstrates the benefits of Azilect® in early Parkinson's disease patients
|
06 August 2010 |
|
Positive pivotal results on escitalopram in Japan
|
18 May 2010 |
|
Lundbeck delivers strong growth
|
07 May 2010 |
|
Novel agent Lu AE04621 enters Lundbeck's development pipeline
|
07 April 2010 |
|
Lundbeck delivers 22 percent revenue growth for 2009
|
05 March 2010 |
|
Lundbeck initiates clinical phase II trials with Lu AE58054
|
30 November 2009 |
|
Novel agent for treatment of Parkinson's disease - Lu 02-750
|
31 October 2009 |
|
Results of ADAGIO study with Azilect® in Parkinson's disease published
|
24 September 2009 |
|
Lundbeck strengthens its research capabilities by acquiring ground-breaking Danish technologies
|
08 July 2009 |
|
Lu AA24530 shows positive results in major depressive disorder phase II study
|
04 July 2009 |
|
Lundbeck receives FDA Complete Response Letter on Serdolect® for the treatment of schizophrenia
|
26 June 2009 |
|
Update on Lu AA21004 clinical development programme in major depressive disorder (MDD)
|
09 June 2009 |
|
Lundbeck meets all of its financial forecasts for 2008 and expects continuing growth in 2009
|
05 March 2009 |